<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2013-19-5-435-441</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-90</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>ГИПЕРГОМОЦИСТЕИНЕМИЯ КАК ФАКТОР СНИЖЕНИЯ ФИБРИНОЛИТИЧЕСКОГО ПОТЕНЦИАЛА ПРИ АКТИВИРОВАННОМ ВНУТРИСОСУДИСТОМ СВЕРТЫВАНИИ</article-title><trans-title-group xml:lang="en"><trans-title>HYPERHOMOCYSTEINEMIA AS A FACTOR OF FIBRINOLYSIS DISTURBANCES  IN PATIENTS WITH ACTIVATED INTRAVASCULAR COAGULATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Субботина</surname><given-names>Т. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Subbotina</surname><given-names>T. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующая лабораторией биохимического мониторинга отдела биохимии научно-исследовательского центра ПСПбГМУ им. акад. И.П. Павлова), ведущий научный сотрудник группы протеомики Института молекулярной биологии и генетики ФМИЦ им. В.А. Алмазова.</p><p>Контактная информация: ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Л. Толстого, д. 6–8, Санкт-Петербург, Россия, 197022. Е-mail: subbotina2002@ mail.ru (Субботина Татьяна Федоровна).</p><p> </p></bio><bio xml:lang="en"><p>Corresponding author: Тhe First Pavlov St Petersburg State Medical University, 6–8 L. Tolstoy, St Petersburg, Russia, 197022. Е-mail: subbotina2002@ mail.ru (Tatiana F. Subbotina, MD, PhD, Professor, the Head of the Laboratory of Biochemical Monitoring at the Biochemical Department of the Research Centre of the First Pavlov St Petersburg State Medical University).</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жлоба</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhloba</surname><given-names>A. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, руководитель отдела биохимии научно-исследовательского центра ПСПбГМУ им. акад. И.П. Павлова, руководитель группы протеомики Института молекулярной биологии и генетики ФМИЦ им. В.А. Алмазова</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет  имени академика И.П. Павлова,  Санкт-Петербург;&#13;
Федеральный медицинский  исследовательский центр имени В.А. Алмазова, Санкт-Петербург</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The First Pavlov St Petersburg State Medical University, St Petersburg;&#13;
Federal Almazov Medical Research Centre, St Petersburg, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2013</year></pub-date><volume>19</volume><issue>5</issue><fpage>435</fpage><lpage>441</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Субботина Т.Ф., Жлоба А.А., 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="ru">Субботина Т.Ф., Жлоба А.А.</copyright-holder><copyright-holder xml:lang="en">Subbotina T.F., Zhloba A.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/90">https://htn.almazovcentre.ru/jour/article/view/90</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Высокая концентрация в крови D-димера является надежным маркером активации внутрисосудистого свертывания, однако не дает однозначной информации о функциональном потенциале системы фибринолиза.</p><p>Цель настоящего исследования заключалась в выяснении вклада гипергомоцистеинемии (ГГци) в нарушения фибринолиза при активированном внутрисосудистом свертывании.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследованы образцы плазмы 141 пациента с активированным внутрисосудистым свертыванием различной этиологии [82 женщины (58,2 %) и 59 мужчин (41,8 %), средний возраст 53,2 ± 7,8 года] с уровнем D-димера &gt; 500 нг/мл, в которых определяли уровень общего гомоцистеина (оГци) с помощью высокоэффективной жидкостной хроматографии. В 57 образцах из общей выборки проведено исследование фибринолитического потенциала с помощью турбидиметрического глобального теста свертывания и фибринолиза с использованием в качестве индукторов тромбина и тканевого активатора плазминогена. Группой сравнения послужили 20 образцов плазмы доноров, подобранных по возрасту и полу.</p></sec><sec><title>Результаты</title><p>Результаты. У 52 пациентов (36,9 %) из общей выборки уровень оГци превышал 12 µM, то есть отмечалась умеренная ГГци. У 29 пациентов (50,9 % обследованных) активация внутрисосудистого свертывания сочеталась с гипофибринолизом, причем частота ГГци в этой группе достигает 58,6 %. В общей выборке обнаружена сильная связь между временем фибринолиза и концентрацией оГци (Rs = 0,564, p = 0,0001).</p></sec><sec><title>Заключение</title><p>Заключение. Таким образом, представляется, что умеренная ГГци является не только одним из факторов риска развития активации внутрисосудистого свертывания, но и вызывает торможение фибринолиза при данном патологическом состоянии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. High blood concentration of D-dimer is a reliable marker of activation of intravascular coagulation, but does not provide unambiguous information about the functional potential of the ibrinolytic system.</p></sec><sec><title>Objective</title><p>Objective. To determine the contribution of hyperhomocysteinemia (HHcy) in ibrinolysis disturbances in patients with activated intravascular coagulation.</p></sec><sec><title> Design and methods</title><p> Design and methods. Plasma samples of 141 patients with activated intravascular coagulation of various etiologies [82 women (58,2 %) and 59 men (41,8 %), mean age 53,2 ± 7,8 years] with the level of D-dimer &gt; 500 ng/ml were studied. The level of total Hcy (tHcy) was determined by high-performance liquid chromatography. In 57 samples ibrinolytic capacity was investigated by turbidimetric global coagulation and ibrinolysis test using as inducers thrombin and tissue plasminogen activator, respectively. 20 samples of donors matched for age and sex served as a comparison group.</p></sec><sec><title> Results</title><p> Results. In 52 patients (36,9 % of the total sample) tHcy level was greater than 12 µM, thus a modest HHcy was observed. In 29 patients (50,9 % of the patients tested for ibrinolysis capacity) the activation of intravascular coagulation was combined with hypoibrinolysis, and the frequency of HHcy in this group reached 58,6 %. A strong correlation between the time of ibrinolysis and tHcy concentration was found (Rs = 0,564, p = 0,0001).</p></sec><sec><title>Conclusion</title><p>Conclusion. Thus, it appears that moderate HHcy is not only one of the risk factors for the activation of intravascular coagulation, but also causes inhibition of ibrinolysis in this pathology.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гомоцистеин</kwd><kwd>фибринолиз</kwd><kwd>внутрисосудистое свертывание</kwd></kwd-group><kwd-group xml:lang="en"><kwd>homocysteine</kwd><kwd>fibrinolysis</kwd><kwd>intravascular coagulation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tripodi A. D-dimer testing in laboratory practice // Clin. Chem. — 2011. — Vol. 57, № 9. — P. 1256–1262.</mixed-citation><mixed-citation xml:lang="en">Tripodi A. D-dimer testing in laboratory practice // Clin. Chem. — 2011. — Vol. 57, № 9. — P. 1256–1262.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yurdakul S., Hekim N., Soysal T. et al. Fibrinolytic activity and d-dimer levels in Behcet’s syndrome // Clin. Exp. Rheumatol. — 2005. — Vol. 23, suppl. 38. — P. S53–S58.</mixed-citation><mixed-citation xml:lang="en">Yurdakul S., Hekim N., Soysal T. et al. Fibrinolytic activity and d-dimer levels in Behcet’s syndrome // Clin. Exp. Rheumatol. — 2005. — Vol. 23, suppl. 38. — P. S53–S58.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Undas A., Zawilska K., Ciesla-Dul M. et al. Altered ibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives // Blood. — 2009. — Vol. 114, № 19. — P. 4272–4278.</mixed-citation><mixed-citation xml:lang="en">Undas A., Zawilska K., Ciesla-Dul M. et al. Altered ibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives // Blood. — 2009. — Vol. 114, № 19. — P. 4272–4278.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumoto T., Wada H., Nobori T. et al. Elevated plasma levels of ibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation // Clin. Appl. Thromb. Hemost. — 2005. — Vol. 11, № 4. — P. 391–400.</mixed-citation><mixed-citation xml:lang="en">Matsumoto T., Wada H., Nobori T. et al. Elevated plasma levels of ibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation // Clin. Appl. Thromb. Hemost. — 2005. — Vol. 11, № 4. — P. 391–400.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Okraska-Bylica A., Wilkosz T., S?owik L., Bazanek M., Konieczy?ska M., Undas A. Altered ibrin clot properties in patients with premature peripheral artery disease // Pol. Arch. Med. Wewn. — 2012. — Vol. 122, № 12. — P. 608–615.</mixed-citation><mixed-citation xml:lang="en">Okraska-Bylica A., Wilkosz T., S?owik L., Bazanek M., Konieczy?ska M., Undas A. Altered ibrin clot properties in patients with premature peripheral artery disease // Pol. Arch. Med. Wewn. — 2012. — Vol. 122, № 12. — P. 608–615.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Toler G.H., D’Agostino R.B., Jacques P.F. et al. Association between increased homocysteine levels and impaired ibrinolytic potential: potential mechanism for cardiovascular risk // Thromb. Haemost. — 2002. — Vol. 88, № 5. — P. 799–804.</mixed-citation><mixed-citation xml:lang="en">Toler G.H., D’Agostino R.B., Jacques P.F. et al. Association between increased homocysteine levels and impaired ibrinolytic potential: potential mechanism for cardiovascular risk // Thromb. Haemost. — 2002. — Vol. 88, № 5. — P. 799–804.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sauls D.L., Lockhart E., Warren M.E., Lenkowski A., Wilhelm S.E., Hoffman M. Modiication of ibrinogen by homocysteine thiolactone increases resistance to ibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia // Biochemistry. — 2006. — Vol. 45, № 8. — P. 2480–2487.</mixed-citation><mixed-citation xml:lang="en">Sauls D.L., Lockhart E., Warren M.E., Lenkowski A., Wilhelm S.E., Hoffman M. Modiication of ibrinogen by homocysteine thiolactone increases resistance to ibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia // Biochemistry. — 2006. — Vol. 45, № 8. — P. 2480–2487.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lauricella A.M., Quintana I., Castanon M., Sassetti B., Kordich L. Inluence of homocysteine on ibrin network lysis // Blood Coagul. Fibrinolysis. — 2006. — Vol. 17, № 3. — P. 181–186.</mixed-citation><mixed-citation xml:lang="en">Lauricella A.M., Quintana I., Castanon M., Sassetti B., Kordich L. Inluence of homocysteine on ibrin network lysis // Blood Coagul. Fibrinolysis. — 2006. — Vol. 17, № 3. — P. 181–186.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhloba A.A., Blashko E.L. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection // J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. — 2004. — Vol. 800, № 1–2. — P. 275–280.</mixed-citation><mixed-citation xml:lang="en">Zhloba A.A., Blashko E.L. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection // J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. — 2004. — Vol. 800, № 1–2. — P. 275–280.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zhloba A.A., Subbotina T.F., Lupan D.S. et al. Arginine and lysine as products of basic carboxypeptidase activity associated with ibrinolysis // Biochemistry (Moscow) Suppl. B: Biomed. Chem. — 2012. — Vol. 6. — P. 261–265.</mixed-citation><mixed-citation xml:lang="en">Zhloba A.A., Subbotina T.F., Lupan D.S. et al. Arginine and lysine as products of basic carboxypeptidase activity associated with ibrinolysis // Biochemistry (Moscow) Suppl. B: Biomed. Chem. — 2012. — Vol. 6. — P. 261–265.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ellman G.L. Tissue sulfhydryl groups // Arch. Biochem. Biophys. — 1959. — Vol. 82, № 1. — P. 70–77.</mixed-citation><mixed-citation xml:lang="en">Ellman G.L. Tissue sulfhydryl groups // Arch. Biochem. Biophys. — 1959. — Vol. 82, № 1. — P. 70–77.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Undas A., Williams E.B., Butenas S., Orfeo T., Mann K.G. Homocysteine inhibits inactivation of factor Va by activated protein C // J. Biol. Chem. — 2001. — Vol. 276, № 6. — P. 4389–4397.</mixed-citation><mixed-citation xml:lang="en">Undas A., Williams E.B., Butenas S., Orfeo T., Mann K.G. Homocysteine inhibits inactivation of factor Va by activated protein C // J. Biol. Chem. — 2001. — Vol. 276, № 6. — P. 4389–4397.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Topal G., Brunet A., Millanvoye E. et al. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin // Free Radic Biol. Med. — 2004. — Vol. 36, № 12. — P. 1532–1541.</mixed-citation><mixed-citation xml:lang="en">Topal G., Brunet A., Millanvoye E. et al. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin // Free Radic Biol. Med. — 2004. — Vol. 36, № 12. — P. 1532–1541.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Harpel P.C., Chang V.T., Borth W. Homocysteine and other sulfhydryl compounds enhances the binding of lipoprotein (a) to ibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism // Proc. Natl. Acad. Sci. USA. — 1992. — Vol. 89, № 21. — P. 10193–10197.</mixed-citation><mixed-citation xml:lang="en">Harpel P.C., Chang V.T., Borth W. Homocysteine and other sulfhydryl compounds enhances the binding of lipoprotein (a) to ibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism // Proc. Natl. Acad. Sci. USA. — 1992. — Vol. 89, № 21. — P. 10193–10197.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Undas A., Brozek J., Jankowski M., Siudak Z., Szczeklik A., Jakubowski H. Plasma homocysteine affects ibrin clot permeability and resistance to lysis in human subjects // Arterioscler. Thromb. Vasc. Biol. — 2006. — Vol. 26, № 6. — P. 1397–1404.</mixed-citation><mixed-citation xml:lang="en">Undas A., Brozek J., Jankowski M., Siudak Z., Szczeklik A., Jakubowski H. Plasma homocysteine affects ibrin clot permeability and resistance to lysis in human subjects // Arterioscler. Thromb. Vasc. Biol. — 2006. — Vol. 26, № 6. — P. 1397–1404.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
